Amarin Corp Plc (AMRN)

[Number sleven]

TTE, Infringement by Hikma doesn't help. They need to invalidate the label. In GSK v Teva they used expert testimony to do this. The "skinny label" failed to carve out the patented indication because there was no way to separate one from the other. I think they are going to do the same thing in Amarin v Hikma. If you want I can dig through the ruling and direct you to the relevant section.
Sleven,